Endometrial Cancer Clinical Trials (April 2026): 330 Recruiting Interventional Studies
Last updated: April 20, 2026
Current Clinical Trial Landscape
Active research areas in 2026:
- IO + chemo as new standard first-line: pembrolizumab (NRG-GY018) and dostarlimab (RUBY) both practice-changing
- ADCs: trastuzumab deruxtecan (T-DXd) for HER2+, sacituzumab tirumotecan, puxitatug samrotecan (B7-H4)
- Lenvatinib + pembrolizumab for pMMR/MSS disease (KEYNOTE-775)
- Molecular classification-guided treatment (POLE, dMMR, p53, NSMP subtypes)
- Fertility-sparing approaches for early-stage endometrioid carcinoma
Standard of care: First-line advanced: carboplatin/paclitaxel + pembrolizumab or dostarlimab (regardless of MMR status). Second-line dMMR: pembrolizumab or dostarlimab monotherapy. Second-line pMMR: lenvatinib + pembrolizumab. MMR/MSI status and p53 mutation are key biomarkers.
Recruiting Trials by Treatment Setting
Advanced / Recurrent — First-Line
IO + chemo is standard. Trials test ADC additions and novel combinations:
- ADC combinations:
- NCT06952504 - Sacituzumab tirumotecan + pembrolizumab vs placebo + pembrolizumab (Phase 3)
- NCT06989112 - DESTINY-Endometrial01: T-DXd + rilvegostomig for HER2+ endometrial cancer (Phase 3)
- NCT07044336 - Puxitatug samrotecan (B7-H4 ADC) vs chemo in B7-H4-selected endometrial cancer (Phase 3)
- Novel IO combinations:
- NCT06340568 - Investigational therapy vs chemo in advanced endometrial cancer (Phase 3)
- NCT06584032 - Fruquintinib + sintilimab for advanced endometrial cancer (Phase 3)
Advanced / Recurrent — Second-Line and Beyond
After first-line IO+chemo failure, HER2-targeted, ADC, and novel agents:
- HER2-targeted:
- NCT05256225 - Trastuzumab/pertuzumab added to chemo for HER2+ uterine cancers (Phase 3)
- NCT07022483 - T-DXd vs standard chemo for HER2-expressing endometrial cancer (Phase 3)
- Novel agents:
- NCT07286331 - GSK5733584 vs chemo in recurrent endometrial cancer (Phase 3)
- NCT07166094 - Rina-S vs investigator's choice in recurrent endometrial cancer (Phase 3)
- NCT07198074 - Bevacizumab + carboplatin/paclitaxel for recurrent endometrial cancer (Phase 3)
- Maintenance:
- NCT05611931 - Selinexor maintenance for p53 wild-type endometrial cancer (Phase 3)
- NCT06712472 - Olaparib maintenance after adjuvant treatment (Phase 3)
Fertility-Sparing Treatment
For young women with early-stage endometrioid carcinoma who want to preserve fertility:
-
- NCT07319429 - Refining fertility-sparing treatment based on molecular classification (Phase 3)
- NCT06379113 - GnRHa + letrozole in obese progestin-insensitive endometrial cancer (Phase 3)
- NCT05316935 - GnRHa + letrozole in non-obese progestin-insensitive endometrial cancer (Phase 3)
- NCT05316467 - Weight management + megestrol acetate in early-stage endometrioid carcinoma (Phase 3)
Showing selected notable trials. View all 330 recruiting interventional trials on ClinicalTrials.gov.
Frequently Asked Questions
How do I find endometrial cancer clinical trials I'm eligible for?
Enter your endometrial cancer details into ClinTrialFinder — including MMR/MSI status (dMMR vs pMMR), p53 mutation, HER2 status, and prior treatments. The AI matches you with trials based on your specific profile in minutes.
What endometrial cancer trials are currently recruiting?
There are 330 recruiting interventional trials for endometrial cancer including checkpoint immunotherapy combinations (pembrolizumab, dostarlimab), ADCs (T-DXd, sacituzumab tirumotecan), lenvatinib combinations, and fertility-sparing approaches.
Find Endometrial Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition.
Find Matching Trials
